Bio-Thera Solutions, the developer of the biosimilar, will continue to hold manufacturing rights in the US market.

Researchers have found in a new research that HLA-B27 genetic marker is linked to a higher risk of various arthropathies, ...

Tofidence is indicated in certain patients for the treatment of moderate to severe rheumatoid arthritis, giant cell arteritis ...

HLA-B27 positivity is linked to higher odds of non-remission in patients with juvenile idiopathic arthritis at 18 years after ...

Dentists are often the first health professionals to see children with arthritis because the temporomandibular joints (TMJ) that enable chewing ...

Indian paediatric rheumatologists discuss early diagnosis and management of rheumatic disorders in children to prevent organ ...

Organon (OGN) stock in focus as the Merck (MRK) spinoff buys rights to Biogen's (BIIB) biosimilar Tofidence, targeting ...

Organon (OGN) announced that it has acquired from Biogen (BIIB) regulatory and commercial rights in the U.S. for Tofidence, a biosimilar to ...

Originally approved by the FDA in September 2023, Biogen's Tofidence became the first tocilizumab biosimilar available in the ...

Organon’s workforce cuts come several months after the company’s loss of exclusivity to its second-largest product, Atozet.

I Gedeon Richter Plc. announces today that the European Medicines Agency has accepted Richter’s marketing authorization application (MAA) for ...